Mosaique Diagnostic

Mosaique Diagnostic is a pioneer in clinical proteomics, leveraging its unique CE-MS platform to decode disease-specific peptide patterns from urine. Its core focus is the early, non-invasive detection and monitoring of chronic diseases, primarily in nephrology, oncology, and cardiology, enabling personalized medicine approaches. The company has commercialized several diagnostic tests in Germany through its subsidiary and maintains an extensive global academic and industry collaboration network. Its technology is backed by a robust publication record and a large proprietary database of human urinary proteome data.

Proprietary CE-MS (Capillary Electrophoresis-Mass Spectrometry) platform for high-resolution analysis of urinary peptides and proteins, combined with advanced bioinformatics for disease-specific pattern recognition.

Mosaique competes in the broad liquid biopsy and clinical proteomics market against companies using mass spectrometry, next-generation sequencing, and immunoassays on various biofluids. Its primary differentiation is its focus on urinary peptide patterns, a robust publication record, and a first-mover advantage in specific renal and urological applications.